Altimmune, Inc.

Good day, ladies and gentlemen, and welcome to the Altamune, Inc. full year and fourth quarter 2023 financial results conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session, and instructions will follow at that time. To ask a question during the session, you will need to press star 1-1 on your telephone. As a reminder, this call is being recorded. I would now like to introduce your host for today's conference call, Rich Eisenstadt, Chief Financial Officer of Altamune. Rich, you may begin.

Thank you, Michelle, and good morning, everyone. Thank you for participating in Altamune's full year and fourth quarter 2023 Financial Results and Business Update conference call. Members of the Altamune team joining me on the call today are Vipin Garg, our Chief Executive Officer, Scott Roberts, our Chief Scientific Officer, and Scott Harris, our Chief Medical Officer. Following the prepared remarks, we will hold a question and answer session. The press release with our lean mass preservation data and our full year and fourth quarter 2023 financial results was issued this morning and could be found on the investor relations section of the company's website. Before we begin, I'd like to remind everyone that remarks about future expectations, plans, and prospects constitute forward-looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. ought to mean cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated. For discussion of some of the risks and factors that could affect the company's future results and operations, please see the risk factors and other cautionary statements contained in the company's filings with the SEC. I'd also direct you to read the forward-looking statement disclaimer in our press release issued this morning and now available on our website. Any statements made on this conference call speak only as of today's date, Wednesday, March 27, 2024, and the company does not undertake any obligation to update any of these forward-looking statements to reflect events or circumstances that occur on or after today's date. As a reminder, this conference call is being recorded and will be available for audio replay on Altamune's website. With that, I will now turn the call over to Dr. Vipengard, Chief Executive Officer of Altamune.

Thank you, Rich, and good morning, everyone. We appreciate you joining us today for a discussion of our year-end and fourth quarter 2023 financial results and business update. We are excited about the 2023 achievements with pembidutide, our GLP-1 glucagon dual receptor agonist, which is in development for the treatment of obesity and MASH, two important clinical indications. Altimmune achieved key milestones in the development of pembidutide last year, including compelling positive data from our 48-week Momentum Phase II obesity trial and initiation of the IMPACT biopsy-driven Phase IIb trial in MASH. We are also extremely pleased with the results of our body composition analysis from the Momentum Phase II obesity trial of pembidutide. showing that 74.5% of weight loss came from fat and only 25.5% from lean mass. Our chief medical officer, Scott Harris, will review these results in greater detail shortly. The MOMENTUM trial showed that subjects receiving pembidutide had a mean weight loss of 15.6% and over 30% of subjects achieved 20% or more weight loss on 2.4 milligrams of pambidutide at week 48, along with robust reductions in BMI and serum lipids, as well as improvements in blood pressure without imbalances in cardiac events, arrhythmias, or clinically meaningful increases in heart rate. In addition to the impressive body composition data, further distinguishes pambidutide from other compounds, in development for the treatment of obesity. Turning to our impact biopsy-driven Phase IIb MASH trial, we are looking forward to announcing the top-line 24-week results anticipated in the first quarter of 2025. We are confident this trial will be successful considering the positive results from our 24-week Phase Ib trial of pembidutide in subjects with MASH-LD where a greater than 75% relative reduction in liver fat content was achieved at the 1.8 milligram and 2.4 milligram doses as 24 weeks, along with robust reductions in ALT and CT1, both myomarkers of liver inflammation. A recently completed preclinical study demonstrating a direct antifibrotic activity of amigutite provides evidence of a potential second mechanism for reducing fibrosis in MASH patients. With that, I will now turn the call over to our Chief Medical Officer, Dr. Scott Harris, to discuss our data and clinical plans. Scott?